New York, November 06, 2024 - PRISM MarketView - Acadia Pharmaceuticals (Nasdaq: ACAD) has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The PRV was awarded to Acadia in March 2023 after the FDA approved DAYBUE™ (trofinetide) for treating Rett syndrome, a therapy licensed from Neuren Pharmaceuticals. Per their agreement, Acadia will pay Neuren one-third of the net proceeds.
Proceeds from the PRV sale will be used to support Acadia’s commercial operations, R&D in central nervous system and rare diseases, and potential future business development. The transaction is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino waiting period. Jefferies LLC advised Acadia on this deal.
The company will announce Q3 results today, November 6 after the market close.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities